Carcinogen macromolecular adducts and their measurement

Carcinogenesis

Volumn 21, Issue 3, 2000, Pages 353-359

  Poirier, Miriam C ^c   Santella, Regina M ^a,c   Weston, Ainsley ^b,c  

^a Joseph L Mailman Sch Pub Hlth C ^*  (United States)

^b Health Effects Laboratory Division   (United States)

^c Carcinogen DNA Interactions Section   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; DNA; PROTEIN;

ANALYTIC METHOD; CANCER RISK; CARCINOGEN DNA INTERACTION; CARCINOGENESIS; DNA ADDUCT; DNA DETERMINATION; DOSIMETRY; ELECTROCHEMICAL DETECTION; FLUORESCENCE SPECTROSCOPY; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MASS SPECTROMETRY; PHOSPHORESCENCE; PRIORITY JOURNAL; PROTEIN MODIFICATION; REVIEW;

EID: 0034092008     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/21.3.353     Document Type: Review

References (84)

1. Miller, E.C. and Miller, J.A. (1947) The presence and significance of bound aminoazo dyes in the livers of rats fed p-dimethylaminoazobenzene. Cancer Res., 7, 469-480.
2. Avery, O.T., MacLeod, C.M. and McCarty, M. (1944) Studies on chemical nature of substance inducing transformation of pneumococcal types: induction of transformation by desoxyribonucleic acid fraction from pneumococcus type III. J. Exp. Med., 79, 137-158.
3. Miller, J.A. and Miller, E.C. (1979) Perspectives on the metabolism of chemical carcinogens. In Emmelot, P. and Kriek, E. (eds) Environmental Carcinogenesis. Elsevier/North-Holland Biomedical Press, Amsterdam, The Netherlands, pp. 25-50.
4. Hemminki, K., Dipple, A., Shuker, D.E.G., Kadlubar, F.F., Segerbäck, D. and Bartsch, H. (1994) DNA Adducts: Identification and Biological Significance. IARC Scientific Publications No. 125, IARC, Lyon.
5. Singer, B. and Grunberger, D. (1983) Molecular Biology of Mutagens and Carcinogens. Plenum Press, New York.
6. Lutz, W.K. (1986) Quantitative evaluation of DNA binding data for risk estimation and for classification of direct and indirect carcinogens. J. Cancer Res. Clin. Oncol., 112, 85-91.
7. Otteneder, M. and Lutz, W.K. (1999) Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts. Mutat. Res., 424, 237-247.
8. Poirier, M.C. (1996) Concepts and mechanisms in carcinogen-DNA interactions. In Hengstler, J.G. and Oesch, F. (eds) Control Mechanisms of Carcinogenesis. Druckerei Thieme, Meissen, Germany, pp. 193-220.
9. Hemminki, K. (1993) DNA adducts, mutations and cancer. Carcinogenesis, 14, 2007-2012.
10. Wild, C.P. and Pisani, P. (1997) Carcinogen-DNA and carcinogen-protein adducts in molecular epidemiology. In Toniolo, P. et al. (eds) Application of Biomarkers in Cancer Epidemiology. IARC Scientific Publications No. 142, IARC, Lyon, pp. 143-158.
11. Tornqvist, M. and Landin, H.H. (1995) Hemoglobin adducts for in vivo dose monitoring and cancer risk estimation. J. Occup. Environ. Med., 37, 1077-1085.
12. Kensler, T.W., Groopman, J.D. and Wogan, G.N. (1996) Use of carcinogen-DNA and carcinogen-protein adduct biomarkers for cohort selection and as modifiable end points in chemoprevention trials. In Stewart, B.W., McGregor, D. and Kleihues, P. (eds) Principles of Chemoprevention. IARC, Lyon, pp. 237-248.
13. Skipper, P.L. and Tannenbaum, S.R. (1990) Protein adducts in the molecular dosimetry of chemical carcinogens. Carcinogenesis, 11, 507-518.
14. Ehrenberg, L. and Tornqvist, M. (1990) Human health risk assessment and biological reactive intermediates: hemoglobin binding. In Witmer, C.M. (ed.) Biological Reactive Intermediates. Plenum Press, New York, pp. 641-647.
15. Poirier, M.C. and Beland, F.A. (1992) DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models: implications for DNA adduct-based human cancer risk assessment. Chem. Res. Toxicol., 5, 749-755.
16. Ehrenberg, L. (1991) Detection and measurement of protein adducts: aspects of risk assessment. Prog. Clin. Biol. Res., 372, 79-87.
17. Groopman, J.D. and Skipper, P.L. (1991) Molecular Dosimetry and Human Cancer: Analytical, Epidemiological and Social Considerations. CRC Press, Boca Raton, FL.
18. Ross, R.K., Yuan, J.M., Yu, M.C., Wogan, G.N., Qian, G.S., Tu, J.T., Groopman, J.D., Gao, Y.T. and Henderson, B.E. (1992) Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339, 943-946.
19. Qian, G.S., Ross, R.K., Yu, M.C., Yuan, J.M., Gao, Y.T., Henderson, B.E., Wogan, G.N. and Groopman, J.D. (1994) A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 3, 3-10.
20. Santella, R.M., Perera, F.P., Young, T.L., Zhang, Y.J., Chiamprasert, S., Tang, D.L., Wang, L.W., Beachman, A., Lin, J.H. and DeLeo, V.A. (1994) Polycyclic aromatic hydrocarbon-DNA and protein adducts in coal tar treated patients and controls and their relationship to glutathione S-transferase genotype. Mutat. Res., 5, 241-247.
21. Wang, L.Y., Hatch, M., Chen, C.J., Levin, B., You, S.L., Lu, S.N., Wu, M.H., Wu, W.P., Wang, L.W., Wang, Q., Huang, G.T., Yang, P.M., Lee, H.S. and Santella, R.M. (1996) Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer, 67, 620-625.
22. Chen, C.J., Wang, L.Y., Lu, S.N., Wu, M.H., You, S.L., Zhang, Y.J., Wang, L.W. and Santella, R.M. (1996) Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology, 24, 38-42.
23. Yuspa, S.H. and Poirier, M.C. (1988) Chemical carcinogenesis: from animal models to molecular models in one decade. Adv. Cancer Res., 50, 25-70.
24. Beland, F.A. and Poirier, M.C. (1989) DNA adducts and carcinogenesis. In Sirica, A.E. (ed.) Pathobiology of Neoplasia. Plenum Press, New York, pp. 57-80.
25. Dipple, A. (1995) DNA adducts of chemical carcinogens. Carcinogenesis, 16, 437-441.
26. Beland, F.A. and Kadlubar, F.F. (1990) Metabolic activation and DNA adducts of aromatic amines and nitroaromatic hydrocarbons. In Cooper, C.S. and Grover, P.L. (eds) Handbook of Experimental Pharmacology. Chemical Carcinogenesis and Mutagenesis I. Springer-Verlag, Heidelberg, Germany, pp. 267-325.
27. Weston, A. (1993) Physical methods for the detection of carcinogen-DNA adducts in humans. Mutat. Res., 288, 19-29.
28. Patel, D.J., Mao, B., Gu, Z., Hingerty, B.E., Gorin, A., Basu, A.K. and Broyde, S. (1998) Nuclear magnetic resonance solution structures of covalent aromatic amine-DNA adducts and their mutagenic relevance. Chem. Res. Toxicol., 11, 391-407.
29. Geacintov, N.E., Cosman, M., Hingerty, B.E., Amin, S., Broyde, S. and Patel, D.J. (1997) NMR solution structures of stereoisometric covalent polycyclic aromatic carcinogen-DNA adduct: principles, patterns, and diversity. Chem. Res. Toxicol., 10, 111-146.
30. Verna, L., Whysner, J. and Williams, G.M. (1996) 2-Acetylaminofluorene mechanistic data and risk assessment: DNA reactivity, enhanced cell proliferation and tumor initiation. Pharmacol. Ther., 71, 83-105.
31. Lehman, T.A. and Harris, C.C. (1994) Mutational spectra of protooncogenes and tumour suppressor genes: clues in predicting cancer etiology. In Hemminki, K., Dipple, A., Shuker, D.E.G., Kadlubar, F.F., Segerbäck, D. and Bartsch, H. (eds) DNA Adducts: Identification and Biological Significance. IARC Scientific Publications No. 125, IARC, Lyon, pp. 399-412.
32. Kinzler, K.W. and Vogelstein, B. (1996) Life (and death) in a malignant tumour. Nature, 379, 19-20.
33. Brash, D.E., Ziegler, A., Jonason, A.S., Simon, J.A., Kunala, S. and Leffell, D.J. (1996) Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J. Invest. Dermatol. Symp. Proc., 1, 136-142.
34. Phillips, D.H. (1990) Modern methods of DNA adduct determination. In Cooper, C.S. and Grover, P.L. (eds) Handbook of Experimental Pharmacology. Springer-Verlag, Heidelberg, Germany, pp. 503-546.
35. Pfeifer, G.P. (1996) Technologies for Detection of DNA Damage and Mutations. Plenum Press, New York.
36. Weston, A. and Poirier, M.C. (1994) Development of methods for chemical carcinogen-DNA adduct determination in human tissues. In Milman, H.A. and Weisburger, E.K. (eds) Handbook of Carcinogen Testing. Noyes Publications, Park Ridge.
37. Poirier, M.C. (1981) Antibodies to carcinogen-DNA adducts. J. Natl Cancer Inst., 67, 515-519.
38. Poirier, M.C. (1993) Antisera specific for carcinogen-DNA adducts and carcinogen-modified DNA: applications for detection of xenobiotics in biological samples. Mutat. Res., 288, 31-38.
39. Strickland, P.T. and Boyle, J.M. (1984) Immunoassay of carcinogen-modified DNA. Prog. Nucleic Acid Res. Mol. Biol., 31, 1-58.
40. Wild, C.P. (1990) Antibodies to DNA alkylation adducts as analytical tools in chemical carcinogenesis. Mutat. Res., 233, 219-233.
41. Muller, R. and Rajewsky, M.F. (1981) Antibodies specific for DNA components structurally modified by chemical carcinogens. J. Cancer Res. Clin. Oncol., 102, 99-113.
42. Kriek, E., Den Engelse, L., Scherer, E. and Westra, J.G. (1984) Formation of DNA modifications by chemical carcinogens. Identification, localization and quantification. Biochim. Biophys. Acta, 738, 181-201.
43. Den Engelse, L., van Benthem, J. and Scherer, E. (1990) Immunocytochemical analysis of in vivo DNA modification. Mutat. Res., 233, 265-287.
44. Santella, R.M. (1999) Immunologic methods for detection of carcinogen-DNA damage in humans. Cancer Epidemiol. Biomarkers Prev., 8, 733-739.
45. 32P-post-labelling assay. Mutat. Res., 378, 1-12.
46. 32P-post-labeling methods for DNA adduct detection: overview and critical evaluation. Drug Metab. Rev., 26, 67-85.
47. 32P-labeling test for DNA damage. Proc. Natl Acad. Sci. USA, 78, 6126-6129.
48. Jeffrey, A.M. (1991) Application of fluorescence to analysis of genotoxicity. In Groopman, J.D. and Skipper, P.L. (eds) Molecular Dosimetry and Human Cancer: Analytical, Epidemiological, and Social Considerations. CRC Press, Boca Raton, FL, pp. 249-261.
49. Yamamoto, Y. and Ames, B.N. (1987) Detection of lipid hydroperoxides and hydrogen peroxide at picomole levels by an HPLC and isoluminol chemiluminescence assay. Free Radic. Biol. Med., 3, 359-361.
50. Hecht, S.S., Carmella, S.G., Foiles, P.G. and Murphy, S.E. (1994) Biomarkers for human uptake and metabolic activation of tobacco-specific nitrosamines. Cancer Res., 54, 1912s-1917s.
51. Fedtke, N. and Swenberg, J.A. (1991) Quantitative analysis of DNA adducts: the potential for mass spectrometric techniques. In Groopman, J.D. and Skipper, P.L. (eds) Molecular Dosimetry and Human Cancer: Analytical, Epidemiological, and Social Considerations. CRC Press, Boca Raton, FL, pp. 171-188.
52. Marnett, L.J. and Burcham, P.C. (1993) Endogenous DNA adducts: potential and paradox. Chem. Res. Toxicol., 6, 771-785.
53. Dingley, K.H., Curtis, K.D., Nowell, S., Felton, J.S., Lang, N.P. and Turteltaub, K.W. (1999) DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relevant dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Epidemiol. Biomarkers Prev., 8, 507-512.
54. Vogel, J.S., Turteltaub, K.W., Finkel, R. and Nelson, D.E. (1995) Accelerator mass spectrometry: Isotope identification at Attomole sensitivity. Anal. Chem., 67, 353A-359A.
55. Hecht, S.S. (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol., 11, 559-603.
56. Shields, P.G., Bowman, E.D., Harrington, A.M., Doan, V.T. and Weston, A. (1993) Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer susceptibility genes. Cancer Res., 53, 3486-3492.
57. Culp, S.J., Gaylor, D.W., Sheldon, W.G., Goldstein, L.S. and Beland, F.A. (1998) A comparison of the tumors induced by coal tar and benzo[a]pyrene in a 2-year bioassay. Carcinogenesis, 19, 117-124.
58. Herron, D.C. and Shank, R.C. (1980) Methylated purines in human liver DNA after probable dimethylnitrosamine poisoning. Cancer Res., 40, 3116-3117.
59. Santella, R.M. (1991) DNA adducts in humans as biomarkers of exposure to environmental and occupational carcinogens. Environ. Cancer Rev., C9, 57-81.
60. Strickland, P.T., Routledge, M.N. and Dipple, A. (1993) Methodologies for measuring carcinogen adducts in humans. Cancer Epidemiol. Biomarkers Prev., 2, 607-619.
61. Schut, H.A. and Shiverick, K.T. (1992) DNA adducts in humans as dosimeters of exposure to environmental, occupational, or dietary genotoxins. FASEB J., 6, 2942-2951.
62. Poirier, M.C. (1997) DNA adducts as exposure biomarkers and indicators of cancer risk. Environ. Health Perspect., 105 (Suppl. 4), 907-912.
63. Shuker, D.E. and Farmer, P.B. (1992) Relevance of urinary DNA adducts as markers of carcinogen exposure. Chem. Res. Toxicol., 5, 450-460.
64. Harris, C.C., Trump, B.F., Grafstrom, R. and Autrup, H. (1982) Differences in metabolism of chemical carcinogens in cultured human epithelial tissues and cells. J. Cell Biochem., 18, 285-294.
65. Tang, D.L., Rundle, A., Warburton, D., Santella, R.M., Tsai, W.Y., Chiamprasert, S., Hsu, Y.Z. and Perera, F.P. (1998) Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis, 19, 1949-1953.
66. Tang, D., Santella, R.M., Blackwood, A.M., Young, T.L., Mayer, J., Jaretzki, A., Grantham, S., Tsai, W.Y. and Perera, F.P. (1995) A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol. Biomarkers Prev., 4, 341-346.
67. Perera, F., Mayer, J., Jaretzki, A., Hearne, S., Brenner, D., Young, T.L., Fischman, H.K., Grimes, M. Grantham, S. and Tang, M.X. (1989) Comparison of DNA adducts and sister chromatid exchange in lung cancer cases and controls. Cancer Res., 49, 4446-4451.
68. Spivack, S.D., Fasco, M.J., Walker, V.E. and Kaminsky, L.S. (1997) The molecular epidemiology of lung cancer. Crit. Rev. Toxicol., 27, 319-365.
69. Godschalk, R.W., Ostertag, J.U., Moonen, E.J., Neumann, H.A., Kleinjans, J.C. and van Schooten, F.J. (1998) Aromatic DNA adducts in human white blood cells and skin after dermal application of coal tar. Cancer Epidemiol. Biomarkers Prev., 7, 767-773.
70. van Schooten, F.J., Hillebrand, M.J., van Leeuwen, F.E., van Zandwijk, N., Jansen, H.M., Den Engelse, L. and Kriek, E. (1992) Polycyclic aromatic hydrocarbon-DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels in lung. Carcinogenesis, 13, 987-993.
71. Santella, R.M. (1997) DNA damage as an intermediate biomarker in intervention studies. Proc. Soc. Exp. Biol. Med., 216, 166-171.
72. Kensler, T.W. and Groopman, J.D. (1997) Carcinogen-DNA and protein adducts: Biomarkers for cohort selection and modifiable endpoints in chemoprevention trials. J. Cell Biochem., 25S, 85-91.
73. Hecht, S.S. (1997) Tobacco and cancer: approaches using carcinogen biomarkers and chemoprevention. Ann. NY Acad. Sci., 833, 91-111.
74. Skipper, P.L., Peng, X., Soohoo, C.K. and Tannenbaum, S.R. (1994) Protein adducts as biomarkers of human carcinogen exposure. Drug Metab. Rev., 26, 111-124.
75. Osterman-Golkar, S. and Ehrenberg, L. (1982) Covalent binding of reactive intermediates to hemoglobin as an approach for determining the metabolic activation of chemicals-ethylene. Drug Metab. Rev., 13, 647-660.
76. Skipper, P.L. (1996) Influence of tertiary structure on nucleophilic substitution reactions of proteins. Chem. Res. Toxicol., 9, 918-923.
77. Wieland, E. and Neumann, H.G. (1978) Methemoglobin formation and binding to blood constituents as indicators for the formation, availability and reactivity of activated metabolites derived from trans-4-aminostilbene and related aromatic amines. Arch. Toxicol., 40, 17-35.
78. Farmer, P.B. (1991) Analytical approaches for the determination of protein-carcinogen adducts using mass spectrometry. In Groopman, J.D. and Skipper, P.L. (eds) Molecular Dosimetry and Human Cancer: Analytical, Epidemiological, and Social Considerations. CRC Press, Boca Raton, FL. pp. 189-210.
79. Melikian, A.A., Sun, P. Pierpont, C., Coleman, S. and Hecht, S.S. (1997) Gas chromatographic-mass spectrometric determination of benzo[a]pyrene and chrysene diol epoxide globin adducts in humans. Cancer Epidemiol. Biomarkers Prev., 6, 833-839.
80. Yeowell-O'Connell, K., Jin, Z. and Rappaport, S.M. (1996) Determination of albumin and hemoglobin adducts in workers exposed to styrene and styrene oxide. Cancer Epidemiol. Biomarkers Prev., 5, 205-215.
81. Tornqvist, M. and Kautiainen, A. (1993) Adducted proteins for identification of endogenous electrophiles. Environ. Health Perspect., 99, 39-44.
82. Sherson, D., Sabro, P., Sigsgaard, T., Johansen, F. and Autrup, H. (1990) Biological monitoring of foundry workers exposed to polycyclic aromatic hydrocarbons. Br. J. Ind. Med., 47, 448-453.
83. Bryant, M.S., Vineis, P., Skipper, P.L. and Tannenbaum, S.R. (1988) Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco. Proc. Natl Acad. Sci. USA, 85, 9788-9791.
84. Chen, C.J., Yu, M.W., Liaw, Y.F., Wang, L.W., Chiamprasert, S., Matin, F., Hirvonen, A., Bell, D.A. and Santella, R.M. (1996) Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am. J. Hum. Genet., 59, 128-134.